|
|
|
| Effect of recombinant human brain natriuretic peptide combined with Wenxin Granules in the treatment of end-stage heart failure and its effect on hemodynamics and vascular endothelial function |
| LIU Qi1 SUN Lili2 PANG Zhanqi2 ZHAO Guangren1 XI Yalin1 |
1.Department of pharmacy, Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Liaoning Province, Dalian 116033, China;
2.Department of Cardiovascular Medicine, Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Liaoning Province, Dalian 116033, China |
|
|
|
Abstract Objective To investigate the effect of recombinant human brain natriuretic peptide combined with Wenxin Granules in the treatment of end-stage heart failure and its effect on hemodynamics and vascular endothelial function. Methods A total of 114 patients with end-stage heart failure admitted to Dalian Municipal Central Hospital Affiliated of Dalian Medical University from January to December 2019 were selected and divided into control group and observation group according to random number table method, with 57 cases in each group. The control group was treated with recombinant human brain natriuretic peptide, and the observation group was treated with recombinant human brain natriuretic peptide combined with Wenxin Granules. Both groups were given continuous treatment for four weeks. Clinical efficacy was evaluated after treatment. Left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), left ventricular ejection fraction (LVEF), cardiac output (CO), cardiac index (CI), diastolic function index (O/C), serum B-type natriuretic peptide (BNP) and endothelin-1 (ET-1) levels were compared between the two groups before and after treatment. The incidence of adverse reactions in the treatment process of the two groups was observed. Results The clinical total effective rate of observation group was significantly higher than that of control group (P ＜ 0.05). After treatment, the LVESV, LVEDV, O/C, serum BNP and ET-1 levels in both groups were significantly lower than those before treatment (P ＜ 0.05), and LVEF, CO and CI were significantly higher than those before treatment (P ＜ 0.05). Meanwhile, the LVESV, LVEDV, O/C, serum BNP and ET-1 levels in the observation group were significantly lower than those in the control group (P ＜ 0.05), and LVEF, CO and CI were significantly higher than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Recombinant human brain natriuretic peptide combined with Wenxin Granules has a significant effect in the treatment of end-stage heart failure, which can significantly improve cardiac function and vascular endothelial function, stabilize hemodynamic status, and has good safety.
|
|
|
|
|
|
[1] 陈新，周音频.终末期心力衰竭辅助装置并发症研究进展[J].心血管病学进展，2019，40（3）：471-474.
[2] 王玉君.难治性心力衰竭的治疗及护理进展[J].中国城乡企业卫生，2019，34（8）：76-78.
[3] 黄峥，底瑞青，白井双，等.基于NICE指南的姑息护理在心力衰竭终末期患者中的应用[J].中华现代护理杂志，2019，25（13）：1655-1658.
[4] 王颖，姜世平.重组人脑利钠肽治疗终末期心力衰竭临床评价[J].中国药业，2019，28（2）：61-64.
[5] 王进华，汪庆玲，黄春燕.稳心颗粒治疗心力衰竭合并心房颤动疗效研究[J].山西医药杂志，2019，48（14）：1720-1722.
[6] 陆再英，钟南山.内科学[M].7版.北京：人民卫生出版社，2008：165-178.
[7] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：77-84.
[8] 王宙，周琳，刘洋，等.慢性心力衰竭的流行病学研究现状及其防治研究进展[J].中国循证心血管医学杂志，2019， 11（8）：1022-1024.
[9] 王双，冯景辉，吴丽馨，等.脑啡肽酶抑制剂对心力衰竭患者认知功能的研究进展[J].心血管病学进展，2019，40（9）：1253-1256.
[10] 刘光发，陈伟雄，胡慧芳，等.重组人脑利钠肽对脓毒症合并心肾综合征患者的治疗作用[J].临床急诊杂志，2020， 21（6）：478-481，487.
[11] 武剑华.内科治疗难治性心力衰竭的研究进展[J].中国社区医师，2018，34（32）：5，7.
[12] 许稽松.重组人脑利钠肽治疗重症心力衰竭患者的临床效果观察[J].临床合理用药杂志，2020，13（17）：119-120.
[13] 张何璐，刘福明.难治性心力衰竭中医辨治特点[J].世界最新医学信息文摘，2019，19（50）：247-248.
[14] 青黛.稳心颗粒：心衰治疗好帮手[J].医师在线，2017，7（33）：33.
[15] 王燕飞，王登峰.稳心颗粒联合胺碘酮治疗老年心力衰竭合并心房颤动临床效果及对凝血功能及细胞因子水平的影响[J].中国老年学杂志，2019，39（21）：5148-5151.
[16] 马秀梅.稳心颗粒治疗慢性心力衰竭心悸的临床效果观察[J].中西医结合心血管病电子杂志，2020，8（14）：44.
[17] 杜曼.稳心颗粒辅助治疗快速心律失常合并心力衰竭的临床效果[J].中国民康医学，2020，32（8）：96-98.
[18] 朱学花，申平鑫，蔡华.稳心颗粒联合重组人脑利钠肽治疗终末期心力衰竭的临床研究[J].现代药物与临床，2020，35（5）：927-932.
[19] 吴代琴，郭海俊，廖付军，等.重组人脑利钠肽治疗急性心力衰竭疗效观察[J].中国实用医药，2020，15（11）：8-10.
[20] 蒋璐，龚国彪，康小兰，等.重组人脑利钠肽对严重心力衰竭患者心肌纤维化标志物水平的影响[J].疑难病杂志，2020，19（10）：1005-1008.
[21] 吴玉梅.重组人脑利钠肽联合硝普钠治疗对急性失代偿性心力衰竭患者ST2、hs-CRP、IL-6水平的影响及疗效观察[J].中国处方药，2019，17（10）：119-120.
[22] Dokainish H. Assessing hemodynamics noninvasively in patients with heart failure [J]. Curr Opin Cardiol，2016， 31（5）：493-500.
[23] 丁国雷，袁烁，张威威.心力衰竭患者血管外肺水指数及肺部超声B线数目相关性研究[J].世界最新医学信息文摘，2019，19（78）：85，87.
[24] 何刚，刘红旭，周琦，等.应用脉搏指示连续心排血量监测技术评价左西孟旦注射液联合参附注射液对重症射血分数降低型心力衰竭住院患者血流动力学的影响[J].中国医药，2020，15（4）：508-512.
[25] 张莹洁，任岩春，赵永峰，等.急诊PCI术后早期应用脑钠肽对急性心肌梗死患者神经内分泌激素、血管内皮功能及心功能的影响[J].疑难病杂志，2020，19（5）：447-451.
[26] Qin L，Liu X，Li Y. Correlation of serum BNP and ET-1 levels with cardiac pump function and ventricular remodeling in patients with heart failure[J]. Cell Mol Biol（Noisy-le-grand），2020，66（3）：125-131.
[27] 郭飞波.CypA，BNP，ET-1浓度在老年慢性心衰患者中的表达及临床意义[J].现代检验医学杂志，2016，31（6）：88-91. |
|
|
|
